BzATP (triethylammonium salt)

O[C@@H]1[C@H](O[C@H]([C@@H]1OC(C(C=C2)=CC=C2C(C3=CC=CC=C3)=O)=O)N4C5=NC=NC(N)=C5N=C4)COP(OP(OP([O-])(O)=O)([O-])=O)([O-])=O.O=C(O[C@@H]6[C@H](O[C@H]([C@@H]6O)N7C8=NC=NC(N)=C8N=C7)COP(OP(OP([O-])(O)=O)([O-])=O)([O-])=O)C(C=C9)=CC=C9C(C%10=CC=CC=C%10)=O.CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC

[1]B R Bianchi, et al. Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur J Pharmacol. 1999 Jul 2;376 (1-2) :127-38.|[2]Mark T Young, et al. Amino acid residues in the P2X7 receptor that mediate differential sensitivity to ATP and BzATP. Mol Pharmacol. 2007 Jan;71 (1) :92-100.|[3]Zhenhua Ji, et al. Involvement of P2X 7 Receptor in Proliferation and Migration of Human Glioma Cells. Biomed Res Int. 2018 Jan 9;2018:8591397.|[4]Xiuwen Wu, et al. Systemic blockade of P2X7 receptor protects against sepsis-induced intestinal barrier disruption. Sci Rep. 2017 Jun 29;7 (1) :4364.